Abstract:90% of therapeutic programs that enter clinical trials ultimately fail. Human genetic variation provides a set of "natural experiments" that can inform successful strategies for therapeutic discovery. Previous work has estimated that drug targets with human genetics supported mechanisms have a 2-3x increased likelihood of succeeding in the clinic compared to those without. 23andMe, Inc. is a direct-to-consumer genetics company that has created a human genetics dataset approximately an order of magnitude larger in sample size than current publically available cohorts. As of 2024, 23andMe has approximately 15 million individuals with genotype and phenotype data, of which ~80% consent to participation in research. In this work, we explore how both the scale of the genetic data and improved methods to link genetic associations to putative causal genes impact the prediction of clinical success. Comparing the total number of target-indication pairs that have reached at least phase I that are also supported by genetic evidence, the number of target-indication pairs with support from 23andMe is 60% greater than that with support from all GWAS datasets in the public domain. Including 23andMe genetic evidence approximately doubles the number of target-indication pairs in the clinic that are supported by human genetics. Furthermore, we show that genetic associations derived from entirely self-reported phenotypes are 2-3x enriched for clinical success, just as for clinically derived phenotypes. In contrast to conclusions from the recent publication of Minikel et al., we found that minor allele frequencies and effect sizes from GWAS influence the relative success estimates for program approvals, and that drug programs supported by rare and large effect associations have greater (3-4x) likelihood to be approved compared to common variant associations with small effects. Finally, improved gene mapping to identify the likely causal genes underlying genetic associations can result in up to 4-5x enrichment for trial success. With the increased power and scale of the 23andMe genetic dataset, we identify an expansive set of opportunities that may be pursued in the clinic, emphasizing the importance of cohort size and gene mapping confidence in deriving clinical value.

From target discovery to clinical drug development with human genetics

Using human genetics to improve safety assessment of therapeutics

Validating therapeutic targets through human genetics

Target Discovery and Validation in the Post-Genomic Era

The impact on clinical success from the 23andMe cohort

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

Disease coverage of human genome-wide association studies and pharmaceutical research and development

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Genetic factors associated with reasons for clinical trial stoppage

Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networks

Unexplored Therapeutic Opportunities in the Human Genome

A brief history of human disease genetics

The Role of Pharmacogenomics in Rare Diseases

Next-Generation Therapeutics for Rare Genetic Disorders

Genetically Enriched Clinical Trials for Precision Development of Noncancer Therapeutics: A Scoping Review

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomes

Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score

Combining Genetic Proxies of Drug Targets and Time-to-event analyses From Longitudinal Observational Data To Identify Target Patient Populations

Discovery of genetic risk factors for disease